Dow Jones
39.496,96 -15,88 (-0,04%) Nasdaq
16.392,44 +51,57 (+0,32%) Nikkei 225
38.179,46 -49,65 (-0,13%) EUR/USD
1,0799 +0,0027 (+0,25%) Bitcoin EUR
58.429,60 +1.333,67 (+2,34%) CMC Crypto 200
1.301,59 +41,39 (+3,29%)
Atea Pharmaceuticals, Inc. (AVIR)
| Chiusura precedente | 3,8900 |
| Aperto | 3,8900 |
| Denaro | 4,0000 x 200 |
| Lettera | 4,0300 x 200 |
| Min-Max giorno | 3,8800 - 4,0250 |
| Intervallo di 52 settimane | 2,7650 - 5,1900 |
| Volume | |
| Media Volume | 310.039 |
| Capitalizzazione | 337,314M |
| Beta (5 anni mensile) | 0,19 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,6300 |
| Prossima data utili | 06 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 3,50 |
GlobeNewswireAtea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat and present a business update at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 10:10 a.m. ET. A live webcast of the pre
- GlobeNewswire
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environmentEnrollment continues in Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of hepatitis C (HCV) with initial results expected in 4Q23Conference call at 4:30 pm ET today BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceutic
- GlobeNewswire
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 8, 2023, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2023, and to provide a business update. To access the live conference call, pa
